

Jeffrey E. Galpin MD
Curriculum Vitae

July 1st, 2021

Name: Jeffrey Eliot Galpin, M.D.

Business Address: Medical Offices: 5525 Etiwanda Suite 218, Tarzana CA 91356

Phone # / Fax #: (818) 344-6111 and (818) 344-5056

Legal Offices: 2675 Rambla Pacifico, Malibu CA 90265

Fed. Tax ID 95-3696113

Date / Place of Birth: June 19, 1945/Chicago, Illinois

Citizenship: United States of America

Marital Status: Married– Carrie Galpin
Combined
(11 children and 14 Grandchildren)

Education:

1962-66 University of Illinois, B.A.
Major in Modern Drama, Existential Theater, and Cellular Biology

1966-70 University of Illinois,
College of Medicine, M.D.

Medical Board Certifications:

1973 American Board of Internal Medicine

1976 American Board of Internal Medicine, Infectious Diseases

Medical Licensures:

State of California (#G22170)
DEA (#AG7967180)
NPI# (1386679561)

Postgraduate Position:

- 1970-71 Medical Intern
Presbyterian St. Luke's Hospital
Chicago, Illinois
- 1971-72 Resident, Medicine
Presbyterian St. Luke's Hospital
Chicago, Illinois
- 1972-73 Resident, Medicine
Wadsworth Veterans Administration Hospital
University of California, Los Angeles
Los Angeles, California
- 1973-75 Post-Doctoral Fellow, Infectious Disease
Harbor General Hospital
University of California, Torrance, California
- 1975-76 Fellowship Grant Supported Through
National Institutes of Health
Bethesda, Maryland
- 1975-77 Postgraduate Research, Molecular Biology University of California, Irvine
Irvine, California
Supported by National Young Administrator Award in Medical Program for
Veterans Administration lasting 4 years with Research Grants and Salary
(with David T. Kingbury, Ph.D.)
- 1978-1979 Genetic Engineering and Medical Molecular Biology
Cal Tech (Leroy Hood) with Peptide Synthesizer and Protein Sequencer

Work Experience:

- 1972- Present Doctor Galpin is Board Certified in Internal Medicine and Infectious
Disease. He has been treating and giving continued care for patients
since 1972.
- Doctor Galpin was also the Chairman of Shared Medical Research
Foundation, a not-for-profit research foundation, and is the Principal
Investigator for all the studies that was conducted at that Foundation.
Developed and ran the first HIV Community Hospital Dedicated Unit
at Sherman Oaks Hospital then under ownership of Marv Strin.
- 1996-1998 Partner at Valley Healthcare Partners, Sherman Oaks,
CA

1998-2001	Partner at AVALAR Medical Group, Tarzana, CA
2001-2002	Partner at PHIND Medical Group, Tarzana, CA
2002-Present	Jeffrey E. Galpin, MD, Inc., Tarzana, CA

Academic Appointments:

1977-80	Assistant Professor of Medicine University of California, Los Angeles Los Angeles, California
1980-81	Associate Professor of Medicine University of California, Los Angeles Los Angeles, California
1981-82	Associate Professor of Medicine University of California, Los Angeles Los Angeles, California
1991-present?	Associate Professor of Medicine University of Southern California Los Angeles, California

Distinctive Career Accomplishments:

High School

1. Editor of School Newspaper
2. Soloist and 1st Clarinet in Orchestra and Band
3. Ranked National on Chess Team
4. Awarded Grant from James Scholar Program Which Accessed and Supported Independent Study Throughout College, Medical School, and Graduate School; Only one of seven in Illinois
5. Awarded Illinois and Cook County Scholarship for College- Only Perfect Score on Examination in History of Cook County Scholarship Examinations in over 30 years of testing

6. Honor Society
7. Three Time Regional Science Fair Winner

University of Illinois

1. U. of Illinois Wheelchair Football
2. Wheelchair Basketball Illinois and National and International
3. Wheelchair Ping Pong National
4. Wheelchair Track University and International
5. President of the Medical, Nursing, Pharmacy, and Dentistry Student Body for Two Years 1968-70
6. Member of the State of Illinois Advisory Committee on Campus Riots, Minority Programs, and Civil Rights Development with John Gardner and Adlai Stevenson III
7. President of the Honorary Premedical Society
8. Vice President of The Omega Beta Pi Premedical Honorary Fraternity
9. Editor of The Illinois Student Newspaper
10. Humanities and Literature Award U. of Illinois
11. Molecular Biology Student Award

Faculty at UCLA and Wadsworth

1. Chief Postgraduate Training in Medicine, Wadsworth Veterans Administration Hospital- UCLA
2. Associate Professor of Medicine UCLA
3. **Created and Developed Geriatric Research Educational and Clinical Center for UCLA and Wadsworth (GRECC)**
 - a. Established first VA Training Program in Geriatrics
 - b. Researched Immunology of Aging

- c. Set up First Geriatric Ward at UCLA
 - d. Established first Program in Fellowship and Nurse Practitioner Training in Geriatrics
 - e. Established Health Service Research Outcome Programs in Geriatrics
 - f. Created Nationally First 6 Programs in VA System to Treat and Research Geriatrics and Gerontology
 - g. Created Liaison Training Programs with USC Percy Andrus Aging Center and Jewish Home for the Aged
4. Research Advisory Committee for Wadsworth VA Hospital
5. **Consultative Director of Academic Infectious Diseases Teaching Service at Cedars Sinai Hospital (1978-81) Upon Request of Chief of Medicine James Klinenberg**
- a. Established rounds two to three days per week
 - b. Established Combined Pulmonary - Infectious Diseases Conferences
 - c. Established Didactic Topics in Infectious Diseases
 - d. Established Future Need And Direction for Fulltime Academic Teaching Program at Cedars-Sinai
6. Created and Operated One of the Largest Most Competitive Training Programs in Medicine in USA at UCLA Wadsworth VA; in last two years competed with parent University UCLA for Best Internal Medicine and Fellowship Candidates in Country
7. Developed many liaison Programs with Fellow Institutions in LA for Training in Medicine and Fellowship
8. Chief Resident Harbor General Hospital in Medicine
9. **Fellowship Through NIH**
- a. Research and Development into Tumor Virus Molecular Biology
 - b. Research into Immunology of Viruses and Mycoplasma and Chlamydia
 - c. Diagnostics Molecular Probes for diagnosing Infectious Diseases

- d. Research into the viral cause of Diabetes
- e. Research into the infective cause of Ulcers
- f. Research into the viral and infective cause of Rheumatoid Arthritis
- g. Research into the immunology and infective causes of Perimyocarditis and Arteriosclerosis
- h. Diagnosis and Treatment of Sexually Transmitted Diseases

Other Activities While Training, and Academic Work

- 1. Active in Civil Rights Movement in 1960s and 70s
- 2. Fiction and Science Fiction Writer
- 3. Applied the use of Passive Immunotherapy to treating progressing HIV patients using long term surviving processed plasma in the early evolution of HIV Care
- 4. Active in Political Support
 - a. Student Leader in Chicago for Robert Kennedy Presidential Campaign
 - b. Active in Campaign for President Clinton

PORTON INTERNATIONAL INC. AND PORTON DOWNS, ENGLAND

- 1. **Founded, Developed or Advised 5 Biotechnology Companies working with Porton Downs International Inc. in England whose CEO Wensley Haydon-Baillie is the Earl of Oxford – that allowed and honored me with the opportunity to do research in England at Porton Downs, England NIH equivalent to US and NATO Headquarters for Biowarfare and**

other Research), Thailand, and the United States that was center for world virus containment including first strains of HIV, Lassa Fever, and viruses like EBOLA. Consulted and helped develop new approaches to containment and treatment while researching and applying new diagnostics. This was also NATO Center for work in Global Infection Control and Advise

1. Research in Geographic Biomagnetism as to Epidemiology of Specific Illnesses through University of Chicago, Argonne National Laboratory
2. Research elective with Leroy Hood PhD at Cal Tech in developing First Protein Synthesizer
3. Research at Cal Tech in developing Ist Logic Internal Medicine Physician Through Linking IBM34 and 36 Computers with Tree System Algorithms
4. Research as Principle Investigator for First Gene Therapy in The United States tried in HIV disease under Viagene Inc.
5. Research in the first Application of Vasoactive Neuropeptides in Treating Diseases of Allostatic Stress and acting as a regulator of adaptive and innate immunity
6. Research under Support from Bristol Myers Squibb using hydroxyurea and other antineoplastic agent to control and treat HIV/AIDS and received BMS Researcher of the Year Award for ongoing work and Clinical Trials Advisory and Management
7. Researched first Rapid DNA based Molecular Diagnostics for Infectious Diseases with David Kingsbury PhD

Professional and Research Experience:

1976-81 Faculty, Infectious Diseases
Harbor General Hospital
Torrance, California

1977-81 Chairman, Intern Selection
Wadsworth Veterans Administration Hospital
Los Angeles, California

1977-81 Director of Intensive Care Unit
Wadsworth Veterans Administration Hospital
Los Angeles, California

1977-81 Member, Research Committee
Wadsworth Veterans Administration Hospital; Los Angeles, California

1977-81 Faculty, Infectious Diseases
Wadsworth Veterans Administration Hospital
Los Angeles, California

1977-81 Chief, Postgraduate Training in Medicine
Wadsworth Veterans Administration Hospital
Los Angeles, California

1978-81 Director of Education,
Geriatric Research Education and Clinical Center
Wadsworth Veterans Administration Hospital
Los Angeles, California

1978-81 Academic Consultant, Infectious Diseases Program
Cedars-Sinai Medical Center
University of California, Los Angeles
Los Angeles, California

1981- 2008 Staff Physician, Medicine and Infectious Diseases
Encino Hospital
Encino, California

1981-1986 Staff Physician, Medicine and Infectious Diseases
Northridge Hospital
Northridge, California

1981- 2009 Staff Physician, Medicine and Infectious Diseases
Tarzana Regional Medical Center

	Tarzana, California
2009 – Present	Staff Physician, Medicine and Infectious Diseases Providence Cedars Sinai Tarzana Regional Medical Center Tarzana, California
1982-1999	Staff Physician, Medicine and Infectious Diseases Sherman Oaks Hospital Sherman Oaks, California
1984-86	Hospital Epidemiologist Encino Hospital Encino, California
1986-88	Hospital Epidemiologist Tarzana Regional Medical Center Tarzana, California

Consultantships, Directorships, and Advisory Boards:

1980-82	Founder, and Member, Board of Directors ImmuDx Corporation Woodland Hills, California
1983-84	Member, Board of Directors Medevac San Diego, California
1984-86	Founder, and Member, Board of Directors International Medical Diagnostics San Francisco, California
1983-90	Advisor, The Center for Applied Microbiology Research London, England
1984-90	Member, Board of Directors Biotechnology Research and Development Corporation Porton International London, England
1986-90	Founder, and Member, Board of Directors Porton Medical Laboratories Sherman Oaks, California
1986-90	Director, Porton International Immunology and Infectious Disease Division Encino, Sherman Oaks, Tarzana, California

1986-90	Director, International Genetics Biological Products, Inc. San Francisco, California
1990- 2010	President, Shared Medical Research Foundation Tarzana and Sherman Oaks, California
1991-1994	National Director for Community Research Caremark International, Inc. Lincoln Shire, Illinois
1991-1994	Director, Health Research Network, Inc. Subsidiary of Caremark International, Inc. Lincoln Shire, Illinois
1997- 2003	Director of Clinical Development Exponential Biotherapies, Inc.
1995-	Scientific Advisory Committee Immuni-T Inc.
1998-	Board of Directors, Focused Managed Research
2003- 2005	President, Future Immunomodulating Research for Systemic Therapeutics, LLC (F.I.R.S.T.), Tarzana, CA
2006- 2009	Board of Advisors Brain Matters Inc.
2006 - 2009	CEO/President Peptide T Holdings Inc.
2014 -2015	Chief Medical Advisor and Principal Investigator for Rapid Pharma
2014 -	Chairman and Founder of "PULSER INC" (Physicians' Unified Library for Sharing Electronic Records
2019 -	Co-Founder and CMO of EntellAM LLC (A Vision of Medical Analytics)

Advisory Positions / Task Forces

1980 -	Infectious Disease Alert – News Letter Published Nationally – editor for 10 years and then editor emeritus under Stan Deresinski MD (National Distribution)
1990-1992	Advisory Committee, Amgen PI Erythropoietin Development
1994-1997	Member, Scientific Advisory Committee Collaborative Clinical Research, Inc.

Cleveland, Ohio

1994-1995	Member, Board of Directors Medical Alliance for Research Studies Houston, Texas
1993-1995	Scientific Advisory Board Viagene Inc.
1993-1995	Scientific Advisory Board AES Inc.
1994-1996	Scientific Task Advisory for Abbott Labs. Protease inhibitor
1995-2004	Scientific Advisory Board Advanced Peptides Inc.
1995-2005	Core Group of Gene Therapy Task Force USC, UCLA, Children's Hospital L.A., City of Hope, Shared Medical Research Foundation
1987- 1992	Johnson & Johnson (Formally Immunobiology Research Institute)- Advisory Board-Immune Modulator- TP-5
1990- 1993	Hoffman La Roche- Advisory Board- ddC
1999- 2003	Serono- Advisory Board/Task Force- Growth Hormone
1998- 2004	Unimed- Advisory Board- Marinol
2003- 2004	Purdue Fedderick- Advisory Board-New Neuropathic pain agent
2000- 2004	Boehringer Ingelheim- Advisory Board-protease inhibitors/Hepatitis B
1993- 1996	Merck- Advisory Board- HIV agents
2000- 2006	Glaxo Smithkline- Advisory Board
2000- 2003	Agouron-Pfizer- Advisory Board
2014 -	Founder and CEO PULSER LLC
2019 -	CMO for EntellAM LLC
2020 -	Covid Pandemic Task Force of PSJH and its 52 Hospitals in 5 States
2020 -	Covid Task Force for Providence Cedars Sinai Tarzana Hospital
2021 -	Executive Council Research and Development PSJH

Biotechnology Experience and Accomplishments

1. Modeled and designed 9 Biotechnology Companies
2. Created Protocols For Approximately 40 Diverse Projects Within Biotechnology Field
3. **Presented and obtained Approval From Both FDA and NIH Agencies for IND and Milestone Gene Therapy Research Programs**
4. Developed Programs to Assess and Critically Review Biotechnology Research Platforms bringing together research, clinical, and community activist groups
5. Developed diagnostic markers and assessed outcomes for multiple studies involving advisory role to many of the world's major biotech and pharmaceutical corporations
6. Developed strategic Programs for Research Development for many medical products and diagnostics working in close association with Biotech and Pharm Research Divisions
7. Developed Two Research Reference Laboratories Specializing in Molecular and Immunologic Diagnostics
8. Developed three National Research Networks to Encourage Community Based Clinical Research
9. Assessed and Consulted for Several Financial Brokerage Houses the Scientific and Economic Worth and Value of Biotechnology Companies and Their Research Concepts and Technologies
10. Projected and created strategic Plans to Develop and Assess New Technology Platforms for Financial Investors in The United States and Europe
11. Collaborated on Three Program Projects for the NIH including the areas of: Sexually Transmitted Diseases, Community AIDS Network, and The Molecular Biology and Pathogenesis of Sexually Transmitted Diseases
12. Created A National Research Network Which Evolved and Was Acquired as A Subsidiary of Dunn and Bradstreet Inc.
13. Established first IND for use of peptide T for treating PML
14. Established first IND drug study for use of hydroxyurea for HIV therapy, for Bristol Myers-Squib(BMS)

15. Preparing First IND on Use of Phage for Treatment of Resistant Bacteria, for Exponential Biotherapies Inc.
16. Preparing IND for Use of UFT as a New Approach To Aggressive Therapy For HIV-1, for BMS
17. Spoke before the Congressional Committee on Veteran Affairs as a consultant on Traumatic Brain Injuries (TBIs) and Post Traumatic Stress Disorders (PTSD) and there pathophysiology and potential new molecular therapeutics.

Professional Organizations – Many To Present Date - :

1973	American College of Physicians
1973	American Society of Microbiology
1978	Directors of Medical Training Program Group
1978	American Geriatric Society
1979	American Program Directors in Internal Medicine
1979	Association Practitioners of Infection Control
1980	Society for Research and Education in Primary Internal Medicine
1981	American Federation of Clinical Research
2001	IDSA Infectious Diseases Society of America
2003	The American Association of Immunologists (AAI)

Awards and Honors:

1962	Illinois State Scholar Recipient
1962	Cook County Vocational Scholar
1962-70	James Scholar (Independent Research Honors Program)
1964-66	Vice President and Member of Pre-Med Honor Society
1968-70	Student President, University of Illinois Medical Center
1969-70	Study Award for Excellence in Clinical Medicine
1970-71	Best Clinical Medicine Instructor Award

1976	R. & E. Associate National Award for Veterans Administration
1976-78	National Institutes of Health Fellowship Grant and Award
1979	National Young Administrator and Faculty Award in Medical Program for Veterans Administration
1995	Manny Mota Foundation Citizen of The Year Award

Research Experience:

1. Program Project Sexually Transmitted Diseases: Pathogenesis and Immunology: UCLA Department of Infectious Diseases and Harbor General Hospital Department Infectious Diseases 1977
2. American Heart Association Grant on Myocardial Biopsy in Viral Perimyocarditis 1978
3. Veterans Administration Project Grant on The Etiopathogenesis of Rheumatoid Arthritis: Wadsworth VA Hospital, UCLA 1974-1981
4. Veterans Administration Project Grant on The Molecular Biology of Sexually Transmitted Diseases: Wadsworth VA Hospital and UCLA 1976-1981
5. Viral Pathogenesis of Diabetes Mellitus: NIH Grant Program 1975
6. Betalysins and other Immunology Factors in Development of Kidney Infections: NIH Fellowship Grant 1974-1976

7. Development of DNA and RNA molecular Probes for the Clinical Diagnosis of Sexually Transmitted Agents: NIH and UCI 1974-1981

8. DNA Chemistry and Genetic Engineering Diagnostic Development: UCLA, UCI, and NIH 1974-1981

9. Immunology of Aging and its Effect on Infectious Diseases: Geriatric Research Education and Clinical Center 1977-1981

10. CMV as a cause of Gastrointestinal Ulceration in Both Peptic Ulcer and Inflammatory Bowel Disease: Wadsworth VA and UCLA 1976-1979

11. Tumor Viruses and Their Molecular Biology: UCI, NIH, and Wadsworth VA Hospital 1974-1980

12. EBV and Other DNA Viruses as Etiology of Prolonged Mild Encephalopathy: UCLA and Wadsworth VA Hospital 1976-1981

13. Development and Clinical Trials with innovative therapeutics and diagnostics to define and treat ie:

1. **Hydroxyurea**
2. **DDI**
3. **Peptide T**

4. **Ist Gene Therapy for HIV approved in US by for therapy in this case HIV by Recombinant DNA Advisory Board of the NIH**

13. **New drug development in family of vasoactive neuropeptides for application to Rx:**

1. **PML (progressive multifocal leukoencephalopathy)**
2. **Ebola and its family of hemorrhagic viruse**
3. **MS (multiple sclerosis)**
4. **Alheimers**
5. **IBD (inflammatory bowel disease)**
6. **Psoriasis**

7. **Other families where cytokine/chemokine modulation controls inflammatory and infectious components 2002-**

14. **Physicians' Unified Library for Sharing Electronic Records (PULSER Inc.) using Big Data with Subtrend Analysis to Accelerate and Create outcome analysis contiuously for Clinical Trials, Health Search Engines, and Consultative Avatars using the linkage and evolution of Electronic Health Records (EHRs) 2013 –**

15. **EntellAM LLC (VISION OF ANALYTICAL MEDICINE)– using Digitized Human Intelligence to simulate and optimize Clinical Research Trial design and their operation to provide and accelerate developing new drugs, diagnostics, and devices within integrated database networks to save time, money, and lives – 2020 – (First Target Developing new Treatments and Preventions for COVID-19 and Predicing Human Disease States and even pandemics Before they Occur by Mathematically Analytically Studying Patterns of Disease Metrics to Predictive Trajectory Endpoints)**

Clinical Research Experience:

1. Principal Investigator: Double-Blind Study of Thymopentin Effects on Patients with HIV-1 Infection; Immunobiology Research Institute (Now a Johnson & Johnson Company), Protocol .07.32.005-88R.
2. Principal Investigator: Double-Blind Study of Thymopentin Effects on Patients with HIV-I Infection; Immunobiology Research Institute(Now a Johnson& Johnson

Company), Protocol H87-047.

3. Principal Investigator: Eprex (Recombinant Human Erythropoietin) Treatment Program for Anemia in AIDS Patients; Amgen, Inc., Protocol I88-083.
4. Principal Investigator: Double-Blind Study of Thymopentin Effects on Patients with HIV-I Infection: Open Label Study; Immunobiology Research Institute(Now a Johnson & Johnson Company), Protocol H87-047.
5. Principal Investigator: Multiple Dose Study to Assess the Pharmacokinetics, Tolerability, and Antiviral Activity of Dideoxycytidine (ddC) in Patients with AIDS or ARC: Treatment Extension; Burroughs Wellcome Company.
6. Principal Investigator: An Open Label Study of the Safety and Efficacy of Eprex in the Treatment of Anemia due to AIDS and AZT Therapy; Amgen, Inc., Protocol J89-026.
7. Co-Investigator: Spiramycin, Protocol CCA901B.
8. Principal Investigator: Treatment Protocol for the Use of Trimetrexate with Leucovorin Rescue for Patients with Pneumocystis carinii Pneumonia and Serious Intolerance to Approved Therapies. Protocol TX301.

9. Co-Investigator: A Study of Trimetrexate with Leucovorin Rescue for Patients who are Ineligible for Randomized Trials of Refractory Pneumocystis carinii Pneumonia. Protocol AS401.
10. Principal Investigator: A Double-Blind Placebo-Controlled Study with Open Label Follow-Up to Determine the Safety and Efficacy of Subcutaneous Doses of r-Huepo in AIDS Patients with Anemia Induced by their Disease and AZT Therapy. Amgen.
11. Principal Investigator: A Double-Blind Placebo-Controlled Study to Determine the Safety and Efficacy of r-Huepo in AIDS Patients with Anemia Induced by their Disease and AZT Therapy. Amgen.
12. Principal Investigator: A Blinded, Randomized Placebo-Controlled Trial of the Safety, Efficacy, and Immunogenicity of a Subunit Vaccine in Persons with Recurrent Genital Herpes. Porton International.
13. Principal Investigator: Double Blind Study Comparing Efficacy of Thymopentin plus AZT. ; Immunobiology Research Institute(Now a Johnson & Johnson Company)
14. Principal Investigator: Rifabutin Prophylaxis for MAI.

15. Principal Investigator: Dose Study of Efficacy for Passive Immunotherapy for Treatment of ARC and AIDS. State of California IND run by Jeffrey Galpin, MD and Marcus Conant, MD.
16. Principal Investigator: Use of Butyl-DNJ Alone and in Combination with AZT for Treatment of HIV Infection. Jansen.
17. Co-Principal Investigator: GM-CSF Combination Therapy for Treatment of MAC Infections.
18. Principal Investigator: A Double Blind, Controlled, Dose Escalating Phase I Clinical Trial to Evaluate the Safety and Biological Activity of HIV-IT (TAF) (HIV-I IIIB env- Transduced, Autologous Fibroblasts) in Asymptomatic HIV-1 Infected Subjects; Viagene, Inc., Protocol HIV-I- 01-1291, U.S. IND No.: BB-4523.
19. Principal Investigator: A Double Blind, Controlled, Dose Escalating Phase I Clinical Trial to Evaluate the Safety and Biological Activity of HIV-IT (V) (HIV-1 IIIB env - Vector) in Asymptomatic HIV-I Infected Subjects; Viagene, Inc., Protocol HIV-I-02-1292.
20. Principal Investigator: Cytotoxic T-Lymphocyte Studies in HIV-1 Infected Subjects; Viagene, Inc., Protocol HIV-RES-04-393.

21. Investigator: d4T (Stavudine) Parallel Track Program; Bristol-Myers Squibb, Protocol AI455-900.
22. Investigator: 3TC™ Open Label Program; Glaxo, Inc., Protocol NUCA3004.
23. Principal Investigator: Double-Blind Study of the Effect of Timuox^R (Thymopentin) on Lymphoproliferative Responses and Virus Load in HIV-Infected Subjects Receiving Nucleoside Analog Anti-Retroviral Therapy; Immunobiology Research Institute(Now a Johnson & Johnson Company), Protocol: .07.32.039-94.
24. Investigator: Open Label Treatment with Timuox^R in HIV-I Infected Patients; Immunobiology Research Institute(Now a Johnson & Johnson Company) Protocol .07.32.008-89.
25. Investigator: Delavirdine (U-90152) in Combination with AZT vs. AZT Alone for Asymptomatic Patients with CD4 Cells Between 200-500 cu mm; The Upjohn Company.
26. Investigator: Delavirdine (U-90152) in Combination with ddI vs. ddI Alone for Patients with CD4 Cells Between 0-300 cu mm; The Upjohn Company.
27. Investigator: Comparative Phase II Multi-Center Study of HIV-1 Infected Patients Treated with Antiretroviral Therapy Alone, Antiretroviral Therapy and rIL-2, or

Antiretroviral Therapy, rIL-2 and Autologous Activated CD8 (+) T-Cells Expanded In Vitro; Applied Immune Sciences, Inc., Protocol AIS-1060-9304.

28. A Phase I/II Open Label Study to Evaluate the Safety and Preliminary Efficacy of Hydroxyurea Alone or in Combination with DDI or DDI plus D4T in HIV-Infected Persons 1995

29. Principal Investigator: Immune Response Vaccine Phase 2/3 Trial for HIV-1

30. Designer and Principal Investigator: Peptide T Therapy for Progressive Psoriasis

31. Designer and Principal Investigator: Competitive Inhibition of GP120 and Growth Hormone for Treatment of Wasting; Advanced Peptides Inc.

32. Designer and Principal Investigator: Treatment of Alzheimer with Neuropeptide Modulation Phase I; Advanced Peptides Inc.

33. Research and Development on B-DNA Diagnostics for CMV and Other Infectious Diseases; Chiron; Series of Studies Under Support of CRADA

34. PRINCIPAL INVESTIGATOR: A Double-Blind, Randomized, Placebo-Controlled Study of AG 1549 in Combination with Viracept and Two Nucleoside Reverse

- Transcriptase Inhibitors in HIV-1 Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen; Agouron, Protocol: AG1549-508.
35. PRINCIPAL INVESTIGATOR: Expanded Access Program for Tenofovir Disoproxil Fumarate (Tenofovir DF) in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options; Gilead Sciences, Protocol: GS-00-955.
36. PRINCIPAL INVESTIGATOR: A Clinical Trial to Determine The Safety and Efficacy of Peptide T in the Treatment of Progressive Multifocal Leukoencephalopathy (PML); Advanced Immuni T, Protocol: 99-400-00.
37. PRINCIPAL INVESTIGATOR: A Prospective, Randomized, Multicenter, Open-Label, Comparative Safety Study of Pegasys® vs. Pegasys® Plus Ribavirin Treatment in Patients with Chronic Hepatitis C; Roche Laboratories, Inc., Protocol: NR16161D.
38. PRINCIPAL INVESTIGATOR: A Phase III Open-Label Safety Study of T-20/Ro 29-9800 (HIV-1 Infusion Inhibitor) in Combination with Oral Antiretrovirals, in Patients who are Unable to Construct a Viable Regimen; Hoffman-LaRoche, Inc. and Trimeris, Protocol: T-20-305/NV16391.
39. PRINCIPAL INVESTIGATOR: A Randomized, Parallel Group,, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone

(Serostim®) in the Treatment of HIV-Associated Catabolism/Wasting; Serono, Inc., Protocol: GF 9037 (IMP 20456).

40. PRINCIPAL INVESTIGATOR: A Randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated with Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected with HIV; Schering.
41. PRINCIPAL INVESTIGATOR: An Open Label, Randomized, Crossover Study To Acceptability And Functionality of Simpleject™ Vs Pre-Filled Syringe(s) when Administered Subcutaneously (SC) Using Kineret™ (anakinra) in Rheumatoid Arthritis Subjects Using Self-Report Questionnaire; Amgen, Inc., Protocol: 20010143.
42. PRINCIPAL INVESTIGATOR: A Study to Evaluate the Erythropoietic Response to Anemia in HCV/HIV Co-Infected Patients Receiving Combination Ribavirin/Interferon Therapy; Ortho-Biotech, Protocol: PR00-30-035.
43. PRINCIPAL INVESTIGATOR: A Study to Evaluate the Erythropoietic Response to Anemia in HCV-Infected Patients Receiving Combination Ribavirin/Interferon or Ribavirin/Pegylated Interferon Therapy: Ortho-Biotech, Protocol: PR00-30-034.
44. PRINCIPAL INVESTIGATOR: Extended Safety Evaluation in Subjects who have

Participated in Chiron Technologies Center for Gene Therapy Retrovirus Protocols:
Chiron Corporation, Protocol: CS-GT005.

45. PRINCIPAL INVESTIGATOR: A Pilot Multi-Center Open Label Study to Determine the Efficacy and Safety of Serostim in HIV Patients with Unintentional Weight Loss or BCM Depletion on Combination Antiviral Therapy with or without Protease Inhibitors; Serono Laboratories, Protocol: IMP 21020.
46. PRINCIPAL INVESTIGATOR: A Randomized, Phase IV Study to Evaluate the Quality of Life of Subjects Infected with HIV-1 and who are Intolerant to Their Current Antiretroviral Therapy and Alter Therapy to Kaletra; Abbott Laboratories, Protocol: M00-267.
47. PRINCIPAL INVESTIGATOR: Atazanavir (BMS-232632) for HIV Infected Individuals: An Early Access Program; Bristol-Myers Squibb, Protocol: AI424900.
48. PRINCIPAL INVESTIGATOR: Multicenter, Open-Label, Early Access Program of Fuzeon (enfuvirtide T-20, RO29-9800, HIV-1 Fusion Inhibitor) in Combination with Free Choice Antiretroviral Regimen to Assess Serious Adverse Events, AIDS Defining Events, and Tolerability in Patients with Advanced HIV-Infection; Hoffman-LaRoche and Trimeris, Protocol: MV 16812B.
49. PRINCIPAL INVESTIGATOR: A Open-Labeled Study to Evaluate the Effect of Every

- Other Week Procrit® (Epoetin alfa) Dosing on Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients; Ortho Biotech, Protocol: PR01-29-024.
50. PRINCIPAL INVESTIGATOR: A Phase IIIB Randomized, Open-Label, Multicenter, Parallel-Arm Study to Evaluate the Short-Term Safety and Tolerability of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered Once-Daily or the Separate Abacavir and Lamivudine Tablet Administered Twice-Daily, as Part of a three or Four Drug Regimen, in Antiretroviral-Naïve HIV-1 Infected Subjects; GlaxoSmithKline; Protocol: ALOHA/101822.
51. PRINCIPAL INVESTIGATOR: A Phase IIIB, Open-Label, Randomized, Multi-center Study Comparing the Antiviral Efficacy, Safety, and Effect on Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, each in Combination with Tenofovir and either Didanosine EC or Stavudine XR in HIV-1 Infected Subjects Receiving a NNRTI-Containing HAART Regimen who are Experiencing their First Virologic Failure; Bristol-Meyers Squibb; Protocol: AI424103.
52. PRINCIPAL INVESTIGATOR: A Double-blind, Randomized, Parallel-group, Pilot Study of Oral Dronabinol versus Placebo in the Prevention of Highly Active Antiretroviral Therapy (HAART)-related Nausea and Vomiting; Solvay Pharmaceuticals; Protocol; S1752101.

53. PRINCIPAL INVESTIGATOR: A Placebo-Controlled, Double-Blind, Parallel Dose Group Study Exploring the Safety, Tolerability, and Virological Effect of 50, 100, and 200mg Reverset™ (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects when used in Combination with other Antiretroviral Agent; Incyte; Protocol; INCB 8721 RVT-203.
54. PRINCIPAL INVESTIGATOR: A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren™ (Natalizumab) in Subjects with Moderately to Severely Active Crohn's Disease with Elevated C-Reactive Protein; Elan Pharmaceuticals; Protocol: ELN100226-CD307.
55. Principal Investigator: Phase I/II trial for MSD on first use of Integrase Inhibitor for HIV Therapy 2005
56. PRINCIPAL INVESTIGATOR: **Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19**
58. PRINCIPAL INVESTIGATOR: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
59. PRINCIPAL INVESTIGATOR: An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy And Safety Of Sarilumab For Hospitalized Patients With covid-19

Medical / Legal Consultantships: (>350 Cases)

Examples of Subjects Included:

1. Plaintiff Against Discrimination for Health Insurance As a Gay HIV Profile
2. Defense of Vaccine Manufacturer for Guillain Barre Claim
3. Consultation for California Board of Medical Quality Assurance on Physician Fraud and Abuse and on Fraud and Abuse in Clinics
4. Defense Support for Wrongful Firing in a Patient With AIDS
5. Plaintiff Support Against Blood Bank in HIV Testing
6. Defense Support of Physician against Claim of Negligence in AIDS Diagnosis
7. Plaintiff Action Against Hospital in Wrongful Death of Child Because of Delayed Diagnosis of Pneumonia and Transporting to Another Hospital without Adequate Stabilization
8. Defense Support of Physician Accused of Negligence in Killer Strept. Cases
9. Plaintiff Action Against Physician who Performed a Breast Lumpectomy which Lead to Necrotizing Gangrene and Death
10. Defense Support of Hospitals and Physicians for Offering Terminally Ill Patient only Supportive Care

Bibliography

Publications:

1. Sleight DR, Galpin JE and Condon, RE: Ulcerative colitis in female monozygotic twins and female siblings. Gastroenterology, 61, 1971.

2. Galpin JE, Chow AW, Yoshikawa TT, and Guze LB: "Pseudoanaphylactic" reactions from inadvertent infusion of procaine penicillin G. *Annals of Internal Medicine*, 81:358, 1974.
3. Bayer AS, Nelson SC, Galpin JE, Chow AW, and Guze LB: Necrotizing pneumonia and emphysema due to clostridium perfringens. *American Journal of Medicine*.
4. Bayer AS, Brenner RJ, Galpin JE, and Guze LB: Severe disabling polyarthritits associated with bacterial endocarditis. *Western Journal of Medicine*, 123:404, 1975.
5. Galpin JE, Chow AW, Yoshikawa TT, and Guze LB: Meningococcal pneumonia: A case report. *American Journal of Medical Science*, 269:247, 1975.
6. Bayer AS, Yoshikawa TT, Galpin JE, and Guze LB: Unusual syndromes of coccidioidomycosis: diagnostic and therapeutic considerations. A report of 19 cases and review of English literature. *Medicine*, 55:131, 1976.
7. Galpin JE, Chow AW, and Guze LB: Sepsis associated with decubitus ulcer. *American Journal of Medicine*, 61:346. 1976.

8. Oill PA, Roser SM, Galpin JE, et al.: Infectious disease emergencies, Part III: patients presenting with respiratory distress syndromes. *Western Journal of Medicine*, 125:452, 1976.
9. Bayer AS, Blumenkrantz MJ, Montgomerie JZ, Galpin JE, Coburn JW, and Guze LB: *Candida* peritonitis. *American Journal of Medicine*, 61:832, 1976.
10. Chow AW, Galpin JE, and Guze LB: Clindamycin for treatment of sepsis caused by decubitus ulcers. *Journal of Infectious Diseases* 135 (supplement):565-568, March, 1976.
11. Oill PA, Galpin JE, and Guze LB: Treatment of cutaneous herpes virus type two infection in Guinea pigs with 9-methoxypsoralan and long wave ultraviolet light. *Journal of Infectious Diseases*, 137:715, 1978.
12. Galpin JE, Shinaberger JN, Stanley TM, Blumenkrantz MJ, Bayer AS, Friedman JZ, Guze LB, Coburn JW, and Glassock AJ: Acute interstitial nephritis due to methicillin. *American Journal of Medicine*, 65:756, 1978.
13. Bayer AS, Galpin JE, Theophilopoulos AN, and Guze LB: Neurological disease associated with mycoplasma pneumoniae pneumonitis: demonstration of viable

mycoplasma pneumoniae in cerebrospinal fluid and blood by radioisotopic and immunofluorescent tissue culture techniques. *Annals of Internal Medicine*, 94 (1):15-20, January 1981.

14. Fischl M, Galpin JE, Levine JD, Groopman JE, et al.: Recombinant human erythropoietin for patients with AIDS treated with Zidovudine. *New England Journal of Medicine*, 323:1069-70, October 1990.
15. Hersh EM, Brewton G, Abrams D, Bartlett J, Galpin JE, et al.: Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized double-blind, placebo-controlled, multi-center study. *Journal of American Medical Association*, 265:1538-44, March, 1991.
16. Ziegner UH, Jolly DJ, Mento SJ, Galpin JE, Prussak CE, Hartnett DE, Bohart C, Barber JR, Peters G, Klump W, Sajjadi N, Merchant B, and Warner JF: Genetic immunization of asymptomatic HIV-1 infected patients with autologous retroviral vector-transduced fibroblasts expressing HIV-1 IIIIB ENV/REV proteins. Submitted, 1994.
17. Warner JF, Jolly D, Mento S, Galpin J, Haubrich R, Merritt J. Retroviral vectors for HIV immunotherapy. *Ann N Y Acad Sci* 1995 Nov 27 772: 105-16

18. Kearns K, Bahner I, Bauer G, Wei SF, Valdez P, Wheeler S, Woods L, Miller R, Casciato D, Galpin J, Church J, Kohn DB Suitability of bone marrow from HIV-1-infected donors for retrovirus-mediated gene transfer. *Hum Gene Ther* 1997 Feb 10 8:3 301-11
19. Skinner GR; Turyk ME; Benson CA; Wilbanks GD; Heseltine P; Galpin J; Kaufman R; Goldberg L; Hartley CE; Buchan A. Department of Infection, University of Birmingham, UK. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. *Med Microbiol Immunol (Berl)* 1997 Jun;186(1):31-6.
20. Duvic M, Friedman-Kien AE, Looney DJ, Miles SA, Myskowski PL, Scadden DT, Von Roenn J, Galpin JE, Groopman J, Loewen G, Stevens V, Truglia JA, and Yocum RC. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials; *Arch Dermatol.* 2000, Dec; 136(12): 1461-9
21. Rosenberg SA; Blaese RM; Brenner MK; Deisseroth AB; Ledley FD; Lotze MT; Wilson JM; Nabel GJ; Cornetta K; Economou JS; Freeman SM; Riddell SR; Brenner M; Oldfield E; Gansbacher B; Dunbar C; Walker RE; Schuening FG; Roth JA; Crystal RG; Welsh MJ; Culver K; Heslop HE; Simons J; Wilmott RW; Boucher RC; Siegler HF; Barranger

JA; Karlsson S; Kohn D; Galpin JE; Raffel C; Hesdorffer C; Ilan J; Cassileth P;
O'Shaughnessy J; Kun LE; Das TK; Wong-Staal F; Sobol RE; Haubrich R; Sznol M;
Rubin J; Sorcher EJ; Rosenblatt J; Walker R; Brigham K; Vogelzang N; Hersh E; Eck
SL: Human gene marker/therapy clinical protocols. Hum Gene Ther 2000 Apr
10;11(6):919-79.

22. Stephanie Gallwitz, Ted Schutzbank, Richard L. Heherling, S. S. Kalter, and Jeffrey E. Galpin: "Smallpox: Residual Antibody after Vaccination". Journal of Clinical Microbiology, September 2003 p. 4068-4070; 0095-1137/03/\$08.00+0 DOI: 10.1128/JCM.41.9.4068-4070.2003.

23. Talal AH1, Liu RC, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonquah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndrome 2011 Nov 1, 58 (3) 261-8

Published Abstracts:

1. Galpin JE, Friedman GS, Shinaberger JH, Shapiro DJ, Blumenkrantz MJ, Stanley TM, Montgomerie JZ, Guze LB, and Coburn JW: Acute interstitial nephritis due to methicillin and similar drugs. The American Society of Nephrology, 8th Annual Meeting, September 1975.

2. Galpin JE, Kingbury DT, Kalmanson G, and Guze LB: The use of ribosomal DNA (rDNA) hybridization for detection of mycoplasma pulmonis in chronically infected mouse joints. Interscience Conference on Chemotherapy and Antimicrobial Agents Annual Meeting, Chicago, Illinois, November 4, 1981.

3. Galpin JE: Recombinant human erythropoietin. International AIDS Conference, Montreal, June, 1989.

4. Galpin JE: Dideoxycytidine (ddC). International AIDS Conference, Montreal, June, 1989.

5. Warner JF, Ziegner U, Peters G, Merchant B, Jolly D, Klump W, Prussak C, Sajjadi N, Mento S, and Galpin JE: An open label, phase I clinical trial of a gene transfer-based immunotherapeutic in HIV-1 infected subjects. Conference on Advances in AIDS Vaccine Development-1993: Sixth Annual NCVDG Meeting, Alexandria, Virginia, October 30-November 4, 1993.

6. Warner JF, Irwin M, Laube L, Lee V, Anderson CG, Chada S, Peters G, Ziegner U, Merchant B, Jolly D, Mento S, and Galpin JE: Retroviral vector vaccines for AIDS Immunotherapy. Keystone Symposia: Prevention and Treatment of AIDS, Hilton Head Island, South Carolina, January 23-30, 1994.
7. Chang H, Warner J, Ziegner U, Peters G, Merchant B, Jolly D, Klump W, Prussak C, Sajjadi N, Mento S, and Galpin JE: An open label, phase I clinical trial of a gene transfer-based immunotherapeutic in HIV-1 infected subjects. Biotechnology Against AIDS-1994: From Basic Science to Prevention, Diagnosis and Therapy, Florence, Italy, April 10-13, 1994.
8. Chang H, Warner J, Ziegner U, Peters G, Merchant B, Jolly D, Klump W, Prussak C, Sajjadi N, Mento S, and Galpin JE: An open label, phase I clinical trial of a gene transfer-based immunotherapeutic in HIV-1 infected subjects. CHI Gene Therapy: New Technologies and applications, Bethesda, Maryland, April 25-27, 1994.

Book Chapters, Supplements, and Proceedings:

1. Bayer AS, Yoshikawa TT, Galpin JE, and Guze LB: Unusual syndromes of coccidioidomycosis. Yearbook of Diagnostic Radiology, 1975.
2. Bayer AS, Nelson SC, Chow AW, Galpin JE, and Guze LB: Necrotizing pneumonia and emphysema due to clostridia perfringens. Yearbook of Diagnostic Radiology, 1976.
3. Galpin JE: Immunity and microbial disease. CRC Handbook on Aging.
4. Galpin JE: Common pulmonary infections. Chapter in Case Oriented Lecture Series, Houghlin Mifflin.
5. Kay MB, Galpin JE, and Makinodan T: Aging, immunity, and arthritic disease. Raven Press, 1980.
6. Galpin JE: Infections in neoplastic disease. Chapter for Bedside Oncology, Little Brown, 1st Edition. 1,2,3 and 4
7. Galpin JE: AIDS. Chapter for Manual of Hematology and Oncology, Little Brown, Edition 1,2,3, and 4.

8. Galpin JE: AIDS. Chapter for Manual of Hematology and Oncology, Little Brown, 2nd Edition.
9. Galpin JE: Management of cutaneous and genital herpes simplex. Outpatient Medicine.
10. Galpin JE: Management of herpes zoster. Outpatient Medicine.
11. Galpin MD JE, Bellman PhD K: Pandemic Situation Awareness Must Support Both Individualized Medicine and Public Health; Invited Paper, COGsima Conference 2021

Editorial Activities:

1982-85	Member, Editorial Board UCLA Medical Newsletter
1981-present	Editor than Editor Emeritus Infectious Disease Alert American Health Consultants, Atlanta, Georgia
1983-89	Consultant

Saunders Publishing

- 1989- Co-Editor, Editor Emeritus
AIDS Clinical Digest
American Health Consultants, Atlanta, Georgia
- 1995- Reviewer
Annals of Internal Medicine
- 2007 - Reviewer
New England Journal of Medicine

Examples of Media Experience

1. Focus of CBS 48 Hours hour program on Viagenes' Gene Therapy HIV Experiment 1995
2. Advisor on Medicine to KABC Radio 1992-1997
3. PBS Radio Marathon on AIDS for World AIDS Day 1992
4. Radiothon for 21 Hours at Playboy Mansion for AIDS, With KABC Radio
5. Advisor and Contributor to Several National Programs as Related To Medical Issues
6. Reported Nationally on CBS Radio Commenting on Illness and Death of Pope John Paul

2005

7. Reported on Avian and Swine Flu on both Fox and ABC News
8. Guest Appearances on Discovery – “Ancient Aliens” 2014-15
9. Town Halls on Covid-19 for Providence Cedars Sinai Tarzana 2020-21
10. Multiple TV interviews on CBS Television about the Covid Pandemic 2020-21

Creative Writing Examples

1. Multiple Short Stories Written under various Pen Names – Mostly Science Fiction
2. With John Hertzfeld Created TV Series for CBS – Dr. Vegas
3. With Bryce Zabel – Created TV Movie – Pandemic
4. With Linda Bloodworth helped create Episode about AIDS for Designing Women TV
5. Guest Presenter on 2011 Series Episode on History Channel - Ancient Aliens, History, and Pandemics
6. Creator and Co-Writer of Pilot Movie for 1 Hour Weekly Drama/Black Comedy “The Laws of Dr. Moses

Examples of Major Lecture Series

1. AMI Series on Update Infectious Diseases 1990- 1994
2. Yearly Review of Progress in HIV/AIDS Research for Being Alive and National Cable Television 1992-1995
3. Keynote Speech Group on Future Biotechnology at Biotech 1986 in Boston
4. Shanti Lecture Series on Development of Counselors for AIDS Support in Los Angeles 1988-present
5. Lecture Series As Member of Los Angeles Task Force on Gene Therapy Which Includes City of Hope, Childrens Hospital, USC, UCLA, and Shared Medical Research Foundation 1995-
6. Lectures in Italy, Hawaii, Seattle, San Francisco, Los Angeles, Denver, and Oakland in 1998- as part of the Bristol-Meyers-Squibb Distinguished Faculty; These include original research in Hydroxyurea and immune restoration of HIV infected patients
7. National 48 Hours CBS 2007 Following 4 Patients with our First Gene Therapy I US Studies with HIV and on Protocol. Teaching How to Perform Research. Was Filmed and Followed for 1 year
8. Lectures in Vancouver, Dallas, Miami, and Los Angeles as part of the Bristol-Meyers-Squibb

Distinguished Faculty; These include topics such as aggressive or eradication therapy for HIV-1 disease 1999

9. Town Rounds Quarterly Lecture Series for Patients and Healthcare Personnel in The San Fernando Valley, California on Updates for HIV-1 Disease. 1st Sponsored By Agouron and Dupont for 1st quarter 1999

10. Lectures in Atlanta, Albany, Augusta, Dallas, Los Angeles, and San Diego as part of the Bristol-Meyers-Squibb Distinguished Faculty for year 2000

11. Lecture Series on AIDS and Sports at CSUN yearly from 1992 – 2007

12. Lecture Series on HIV Disease at Ventura County Hospital UCLA approximately yearly from 1995 – 2005

13. Lecture Series, Townhalls, and Podcasts for Covid Pandemic Updates including new therapeutics and vaccines throughout 2019-Present

14. Guest Consultant:

KABC Talk Radio

NPR (National Public Broadcast Radio)

CBS World Radio

ABC News - Television Los Angeles

NBC News - Television Los Angeles

CBS NEWS – TELEVISION LA